IMS Health
IMS Health is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at IMS Health.
IMS Health is a company.
Key people at IMS Health.
IMS Health was a leading global provider of healthcare data, analytics, technology, and services, primarily serving the life sciences industry including pharmaceutical manufacturers, biotech firms, medical device companies, payers, providers, and governments.[1][2][5][6] It specialized in real-world evidence solutions, workflow analytics, consulting, and massive datasets from over 100,000 suppliers and 45+ billion annual transactions, enabling clients to optimize commercialization, patient outcomes, and operational efficiency.[2][5][6] Headquartered in Danbury, Connecticut, IMS Health processed over 10 petabytes of healthcare data on diseases, treatments, costs, and outcomes across 100+ countries, supporting more than 5,000 clients with proprietary analytics tools like the Multinational Integrated Data Analysis (MIDAS) system.[1][3][6]
IMS Health traces its roots to 1954, when L.W. Frolich (also referred to as Bill Frohlich) and David Dubow founded Intercontinental Marketing Services (IMS) as an extension of Frolich's New York advertising agency, addressing the lack of reliable market data for pharmaceutical "wonder drugs."[1][3][5] The company conducted its first pharmaceutical audit in 1957, entered the U.S. via acquisition in 1969, went public in 1972, and expanded through key buys like Lea Associates (National Disease and Therapeutic Index) and others for hospital and diagnostic data.[1][3] Pivotal moments included launching MIDAS in 1979 for multinational data analysis, forming Medical Communications and Life Sciences divisions in 1973, and spinning off Cognizant Technology Solutions to focus purely on pharma information.[1][3] Acquired by Dun & Bradstreet in 1988 for $1.7 billion and spun out as a public NYSE company in 1998, IMS evolved into a data analytics powerhouse before merging with Quintiles in 2016 to form IQVIA.[2][3][4]
IMS Health rode the wave of big data and real-world evidence in healthcare, transforming fragmented pharma market research into actionable, patient-level insights amid rising demands for evidence-based decisions in drug commercialization, pricing, and outcomes.[4][5] Its timing aligned with the 21st-century shift from sales-focused analytics to AI-driven, connected intelligence, enabling global scale post-1980s acquisitions and pre-merger data dominance.[3][4] Market forces like exploding healthcare data volumes, payer pressures for cost-effectiveness, and regulatory needs for real-world proof favored IMS, positioning it as the largest U.S. physician prescribing data vendor and innovator in cloud analytics.[5][6] By influencing ecosystems through tools for hospitals, providers, and policymakers, IMS accelerated pharma's data-driven evolution, paving the way for merged entities like IQVIA's end-to-end clinical-commercial offerings.[2][4]
IMS Health's legacy as a data pioneer culminated in its 2016 merger into IQVIA, amplifying its impact through combined analytics, clinical research, and AI via IQVIA Connected Intelligence™—a synergy still driving smarter healthcare globally.[2][4] Looking ahead under IQVIA, expect deeper AI integration for predictive outcomes, expanded real-world data applications in personalized medicine, and growth amid trends like value-based care and digital health mandates. This evolution from 1954 market research startup to healthcare intelligence giant underscores IMS's enduring role in powering evidence-based decisions that improve patient lives worldwide, tying back to its founding mission of objective pharma insights.[1][4][5]
Key people at IMS Health.
